Stifel Nicolaus upgraded shares of Edwards Lifesciences (NYSE:EW – Free Report) from a hold rating to a buy rating in a report published on Thursday morning, Ratings reports. The firm currently has ...
Edwards Lifesciences Corp. closed 24.63% below its 52-week high of $96.12, which the company reached on March 28th.
Edwards Lifesciences shares rise as analyst upgrades stock, citing TAVR growth, margin expansion, and strategic business ...
Hosted on MSN2d
Stifel Upgrades Edwards Lifesciences (EW)Fintel reports that on January 30, 2025, Stifel upgraded their outlook for Edwards Lifesciences (NYSE:EW) from Hold to Buy.
In the latest quarter, 11 analysts provided ratings for Edwards Lifesciences EW, showcasing a mix of bullish and bearish ...
Edwards Lifesciences (NYSE: EW) stock rises after Stifel upgrades to Buy, citing potential for TAVR growth acceleration in 2025. Read more here.
Stifel analyst Rick Wise upgraded Edwards Lifesciences (EW) to Buy from Hold with a price target of $90, up from $75. The firm said that TAVR, ...
Shares of Edwards Lifesciences Corp. advanced 4.86% to $72.56 Tuesday, on what proved to be an all-around great trading ...
Medtronic is capturing demand for its cutting-edge solutions, as recent product launches emerge to drive new growth. With the ...
Brighton Jones LLC purchased a new position in Edwards Lifesciences Co. (NYSE:EW – Free Report) in the fourth quarter, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback